Novo Nordisk A/S: Federal Circuit Court rules on patent litigation involving Prandin(R) (repaglinide)


BAGSVAERD, DENMARK--(Marketwired - Jun 18, 2013) - Today, the U.S. Court of Appeals for theFederal Circuit partially affirmed a 2011 District Court decision, with a2-1 ruling that a claim in a Novo Nordisk patent related to the use ofrepaglinide in combination with metformin for the treatment of type 2diabetes was invalid. This decision favors approval and launch of a genericrepaglinide product.

The Federal Circuit also reversed, with a unanimous 3-0 ruling, theDistrict Court decision that Novo Nordisk had committed inequitable conductduring the time the company attempted to acquire the patent.

Novo Nordisk continues to believe in the validity of the patent and isreviewing the ruling. Novo Nordisk expects to provide an update on the casein connection with the announcement of the financial results for the firstsix months of 2013 on 8 August 2013.

Novo Nordisk markets repaglinide under the trade name Prandin® and afixed-dose repaglinide/metformin tablet under the trade namePrandiMet® in the US. In 2012, sales of Prandin® andPrandiMet® in the US amounted to 1.2 billion Danish kroner(approximately 200 million USD).

Novo Nordisk is a global healthcare company with 90 years of innovation andleadership in diabetes care. The company also has leading positions withinhaemophilia care, growth hormone therapy and hormone replacement therapy.Headquartered in Denmark, Novo Nordisk employs approximately 35,000employees in 75 countries, and markets its products in more than 180countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen(Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). Formore information, visit

Company Announcement No 45:

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE


Further information
Mike Rulis
+45 3079 3573
Email Contact

Ken Inchausti (US)
+1 609 240 2919
Email Contact

Kasper Roseeuw Poulsen
+45 4442 4303
Email Contact

Frank Daniel Mersebach
+45 4442 0604
Email Contact

Lars Borup Jacobsen
+45 3075 3479
Email Contact

Jannick Lindegaard (US)
+1 609 786 4575
Email Contact

View Comments (0)